Management of Hyperparathyroidism in Renal Transplant Recipients

Introduction to Treatment Options

The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines suggest that calcitriol (0.60 μg/day) combined with calcium carbonate (1,000 mg/day) can be used in kidney transplant patients with persistent hyperparathyroidism, resulting in a 30-40% decline in PTH values and decreased phosphate supplement requirements from 8.0 to 4.6 g/day 1
Meta-analyses confirm that cinacalcet may provide benefits for patients requiring parathyroidectomy when surgery is contraindicated, although data for kidney transplant recipients are absent from randomized controlled trials 2, 3

The K/DOQI guidelines recommend starting calcitriol at 0.25 μg/day orally for transplant patients with persistent hyperparathyroidism, with monitoring of calcium and phosphorus every 2 weeks in the first month, then monthly 1
Serum corrected calcium must be <9.5 mg/dL before starting calcitriol, and serum phosphorus must be <4.6 mg/dL to reduce metastatic calcification risk 1

Cinacalcet can cause significant hypercalciuria in transplant recipients, potentially leading to renal calculi formation in the transplanted kidney, and requires monitoring of urinary calcium excretion at regular intervals and interval imaging of the transplanted kidney 2, 3
The mechanism of cinacalcet-induced hypercalciuria involves either reduced tubular calcium reabsorption via PTH suppression or direct effects on calcium-sensing receptors in the thick ascending limb of Henle, and patients should be closely monitored for signs of hypercalciuria and nephrolithiasis 2, 3

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines note that cinacalcet effectively corrects both hypercalcemia and hypophosphatemia in kidney transplant recipients with persistent hyperparathyroidism, though it shows no effect on bone mineral density 4

The UK National Institute for Health and Clinical Excellence guidance recommends cinacalcet should NOT be used for routine treatment of elevated PTH in CKD and should be limited to patients with elevated PTH refractory to standard therapy, with normal or high serum calcium, and in whom surgical parathyroidectomy is contraindicated 5, 6
Cinacalcet provides small reductions in risk of surgical parathyroidectomy (RR 0.49) but has little or no effect on all-cause mortality and uncertain effects on cardiovascular death 5, 7

Nausea (RR 2.05) and vomiting (RR 1.95) are common gastrointestinal side effects that occur especially at treatment initiation 5, 8
Cinacalcet increases the risk of hypocalcemia 7-fold overall (RR 7.38), which is the most significant safety concern 9
In X-linked hypophosphatemia patients, cinacalcet should be used with extreme caution as it has been associated with severe adverse effects, namely hypocalcemia and increased QT interval 10